SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing presentation: reset
Phase I Study of Cabotegravir Long-Acting Injectable Formulations Supports ≥4-Monthly Dose Interval
- Sort by:
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
pages: 1
|
presentations:
1 to
1 of
1
|
Phase I Study of Cabotegravir Long-Acting Injectable Formulations Supports ≥4-Monthly Dose Interval (ABSTRACT
130)
Kelong Han
GSK
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
pages: 1
|
presentations:
1 to
1 of
1
|